The BioMed X Institute
19.12.2023 10:03:15 CET | ACCESS Newswire | Press release
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI and Coppercore Inc. Announce Tokenization of High-Grade Copper Resources into Coppercoin(TM)31.3.2026 15:15:00 CEST | Press release
$100 Million in Initial Coppercoin™ Issuance to Set Industry Standard in Tokenized Copper PHILADELPHIA, PA / ACCESS Newswire / March 31, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, and Coppercore Inc. ("Coppercore") today announced the closing of a definitive agreement to digitize and tokenize significant copper resources. The transaction enables Datavault AI to deploy its patented IDE®, DataScore®, and DataValue® blockchain tokenization platform to create Coppercoin™ digital tokens representing pro-rata ownership interests in the underlying in-ground resources. The initial program targets the minting of $100 million or more in Digital Copper Tokens. Coppercoin™ tokens are structured such that each token corresponds to five pounds of underlying high-grade copper resources, with pricing directly linked to the COMEX copper benchmark on a pe
AccessPay Accelerates Growth With Majority Investment From Leading Software Investor, Accel-KKR31.3.2026 10:00:00 CEST | Press release
Financial backing enables AccessPay to scale services for enterprise clients and drive innovation in finance operations MANCHESTER, UK / ACCESS Newswire / March 31, 2026 / AccessPay, a leading bank integration and payment automation provider, has secured a majority investment from Accel-KKR, a prominent global private equity firm specialising in enterprise technology and software companies. The investment is expected to enable AccessPay to fuel the next phase of growth and further its ambition to become a world-class SaaS business driving innovation in the office of the CFO. The investment also opens the door for AccessPay to pursue growth via strategic acquisitions. The office of the CFO faces an increasingly testing operating environment. Alongside cost pressures, increased cyber threats, and a volatile geopolitical climate, AI is fundamentally rewiring finance operating practices. A global McKinsey survey of CFOs from late 2025 reported that 44% of survey respondents had identified
The World's First Agentic CMS Just Got Smarter: Kontent.ai Launches Expert Agents31.3.2026 09:00:00 CEST | Press release
Kontent.ai, the team behind the world's first Agentic CMS, today announced the launch of Expert Agents: purpose-built AI agents that bring deep, specialized intelligence to the content operations teams manage every day. Expert Agents work continuously across content workflows, handling everything that doesn't require human judgment. They can be configured by anyone using simple natural language prompts. BRNO, CZ / ACCESS Newswire / March 31, 2026 / Expert Agents help organizations move faster than ever before, augmenting teams without adding headcount, accelerating campaign launches across markets, improving content performance at scale, and reducing regulatory and compliance risk across even the largest content inventories. The launch marks the next step in Kontent.ai's Agentic CMS vision: a platform where AI agents are embedded directly into the operational layer of content management. At its core, the Agentic CMS combines two layers of intelligence: the Main Agent, which lets teams
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy30.3.2026 16:55:00 CEST | Press release
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development. Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate
CORRECTION: Mandela Dollar ("MUSD") Announced to Promote Mandela's Legacy of Financial Inclusion for Underserved Communities Across the World30.3.2026 16:25:00 CEST | Press release
This Press Release updates the previous version that had incorrect information Datavault AI Inc., Mandela Dlamini & Manaway L.L.C., and Unity Reserve Holdings L.L.C. Launch MUSD Stablecoin to Advance Financial Inclusion and Honor Nelson Mandela's Legacy PHILADELPHIA, PA / ACCESS Newswire / March 30, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset ("RWA") tokenization technologies, Mandela Dlamini & Manaway L.L.C., a Wyoming, USA-based entity ("MDM LLC") dedicated to advancing Nelson Mandela's vision of equality, dignity, and economic empowerment, and Unity Reserve Holdings L.L.C. ("Unity Reserve"), today announced the official launch of Mandela Dollar ("MUSD"), a new USD-pegged stablecoin designed to promote financial inclusion for underserved communities globally. MUSD is designed to serve as a transparent, secure, and accessible digital dollar built on blockchain technology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom